Erasca (NASDAQ:ERAS - Get Free Report) issued its quarterly earnings results on Monday. The company reported ($0.29) earnings per share for the quarter, missing the consensus estimate of ($0.17) by ($0.12), Zacks reports.
Erasca Stock Up 0.4 %
NASDAQ:ERAS traded up $0.01 on Tuesday, hitting $2.60. The stock had a trading volume of 1,894,557 shares, compared to its average volume of 1,514,692. The stock has a market cap of $450.73 million, a price-to-earnings ratio of -3.10 and a beta of 1.17. The business's 50-day simple moving average is $2.58 and its two-hundred day simple moving average is $2.26. Erasca has a 52-week low of $1.51 and a 52-week high of $3.45.
Wall Street Analysts Forecast Growth
Several equities analysts have recently weighed in on the company. HC Wainwright raised their price target on Erasca from $5.00 to $6.00 and gave the company a "buy" rating in a report on Tuesday. The Goldman Sachs Group reduced their price target on Erasca from $7.00 to $4.00 and set a "buy" rating for the company in a report on Tuesday, May 28th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $6.20.
View Our Latest Analysis on Erasca
Insiders Place Their Bets
In other news, Director Alexander W. Casdin bought 80,000 shares of the company's stock in a transaction on Tuesday, May 21st. The shares were acquired at an average cost of $2.27 per share, with a total value of $181,600.00. Following the completion of the transaction, the director now owns 573,974 shares of the company's stock, valued at approximately $1,302,920.98. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders own 21.50% of the company's stock.
Erasca Company Profile
(
Get Free Report)
Erasca, Inc, a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma.
Read More
![Earnings History for Erasca (NASDAQ:ERAS)](https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&Symbol=ERAS)
Before you consider Erasca, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Erasca wasn't on the list.
While Erasca currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.